86505-94-4

Basic information

• Product Name: METHYL 2-AMINO-6-FLUOROBENZOATE
• Synonyms: METHYL 2-AMINO-6-FLUOROBENZOATE;Benzoic acid, 2-aMino-6-fluoro-, Methyl ester;Methyl 2-amino-6-fluorobenzaote
• CAS NO: 86505-94-4
• Molecular Formula: C₈H₈FNO₂
• Molecular Weight: 169.1530232
• Mol File: 86505-94-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 266.6°C at 760 mmHg
• Flash Point: 115°C
• Appearance: /
• Density: 1.264g/cm³
• Vapor Pressure: 0.00857mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: METHYL 2-AMINO-6-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-AMINO-6-FLUOROBENZOATE(86505-94-4)
• EPA Substance Registry System: METHYL 2-AMINO-6-FLUOROBENZOATE(86505-94-4)

Safety Data

• Hazardous Substances Data: 86505-94-4(Hazardous Substances Data)

Usage

General Description

Methyl 2-amino-6-fluorobenzoate is an organic compound with the chemical formula C8H8NO2F. It is a fluorinated derivative of benzoic acid and contains a methyl ester group and an amino group as its functional groups. METHYL 2-AMINO-6-FLUOROBENZOATE is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It has a wide range of applications, including as a building block in the production of various drugs and as an ingredient in the manufacturing of pesticides. Methyl 2-amino-6-fluorobenzoate is a white solid at room temperature and is typically stored and handled under controlled conditions due to its potential reactivity and toxicity.

InChI:InChI=1/C8H8FNO2/c1-12-8(11)7-5(9)3-2-4-6(7)10/h2-4H,10H2,1H3

Upstream product

• 67-56-1 methanol 
• 77326-36-4 2-amino-6-fluorobenzonitrile 
• 1194-65-6 2,6-dichloro-benzonitrile 
• 1897-52-5 2,6 difluorobenzonitrile 
• 434-76-4 2-amino-6-fluorobenzoic acid 
• 212189-78-1 methyl 2-fluoro-3-nitrobenzoate 
• 78755-94-9 5-fluoro-2H-benzo[d][1,3]-oxazine-2,4(1H)-dione 
• 74-88-4 methyl iodide 

Downstream Products

• 120257-01-4 methyl 2-chlorosulfonyl-6-fluorobenzoate 
• 120257-02-5 2-fluoro-6-sulfamoyl-benzoic acid methyl ester 
• 851045-44-8 2-isopropoxycarbonylamino-6-fluoro-benzoic acid methyl ester 
• 221285-25-2 (2-amino-6-fluorophenyl)methanol 
• 1246775-80-3 methyl 2-(benzylamino)-6-fluorobenzoate 
• 1367847-17-3 C₁₅H₁₀FNO₃ 
• 1351528-89-6 5-fluoro-3-(4-fluoro-phenyl)-4-hydroxy-1H-quinolin-2-one 
• 1351528-90-9 3-chloro-5-fluoro-3-(4-fluoro-phenyl)-1H-quinolin-2,4-dione 
• 1351528-91-0 3-azido-5-fluoro-3-(4-fluoro-phenyl)-1H-quinolin-2,4-dione 
• 1351528-84-1 3-amino-5-fluoro-3-(4-fluorophenyl)quinolin-2,4(1H,3H)-dione 
• 1351528-88-5 2-fluoro-6-[2-(4-fluoro-phenyl)-acetylamino]-benzoic acid methyl ester 
• 1448009-57-1 methyl 2-(3-(N,N-diethylsulfamoyl)benzamido)-6-fluorobenzoate 
• 1155288-33-7 C₂₆H₂₆FIN₂O₄ 

Relevant articles and documents

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators

Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553), a potent and brain penetrant NTR1 allosteric modulator.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.